Research progress of immunotherapy in the frontline treatment of adult B cell-acute lymphoblastic leukemia
10.12354/j.issn.1000-8179.2025.20241607
- VernacularTitle:免疫治疗在成人急性B淋巴细胞白血病一线治疗中的研究进展
- Author:
Tian YUN
1
;
Li RUIPING
;
Ma YANPING
Author Information
1. 山西医科大学第二临床医学院(太原市 030001)
- Publication Type:Journal Article
- Keywords:
B cell-acute lymphoblastic leukemia(B-ALL);
immunotherapy;
blinatumomab;
inotuzumab ozogamicin;
chimeric antigen re-ceptor T-cell therapy
- From:
Chinese Journal of Clinical Oncology
2025;52(12):628-632
- CountryChina
- Language:Chinese
-
Abstract:
In recent years,the application of immunotherapy has improved the prognosis of relapsed/refractory(R/R)B cell-acute lympho-blastic leukemia(B-ALL).Blinatumomab,Inotuzumab ozogamicin(InO),and chimeric antigen receptor(CAR)T-cell therapies are the three major immunotherapeutic agents approved for the treatment of R/R B-ALL.This new strategy incorporates immunotherapy into the first line of treatment to reduce the adverse effects of chemotherapy,prolong survival,and expand treatment options for elderly patients.This art-icle discusses new approaches for incorporating immunotherapeutic agents into firstline B-ALL treatment regimens,exploring the potential value of chemotherapy-free regimens in specific patient subgroups,to provide guidance for clinical practice.
